XML 63 R50.htm IDEA: XBRL DOCUMENT
v3.24.3

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) shares in Millions, $ in Millions |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Feb. 22, 2023 USD ($) | Aug. 31, 2024 USD ($) | Jul. 31, 2024 USD ($) | Mar. 31, 2024 USD ($) | Jan. 31, 2024 USD ($) designee shares | Oct. 31, 2023 USD ($) | May 31, 2023 USD ($) | Sep. 30, 2024 USD ($) | Jun. 30, 2024 USD ($) | Mar. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Sep. 30, 2023 USD ($) | Jun. 30, 2023 USD ($) | Mar. 31, 2023 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) | Jan. 30, 2023
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  | $ 505 |  |  |  | $ 91 |  |  | $ 4,674 | $ 808 |  |
Arcus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest, shares (in shares) | shares |  |  |  |  | 30.1 |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership (as a percent) |  |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Arcellx, Inc | Global Strategic Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  | 68 |  |  | $ 101 |  |  | $ 212 |  |  |  |
Maximum potential future milestone payments |  |  |  |  |  |  |  |  |  |  | $ 1,500 |  |  |  |  |  | $ 1,500 |
Payments to acquire equity securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 299 |
Revenue, performance obligation, percentage of U.S. profits |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00%
Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, performance obligation, percentage of U.S. profits |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00%
Arcus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional interest acquired, shares (in shares) | shares |  |  |  |  | 15.2 |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment |  |  |  |  | $ 320 |  |  |  |  |  |  |  |  |  |  |  |  |
Option fee |  |  |  |  | $ 100 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of designees | designee |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |
Arcus | Prepaid and other current assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment |  |  |  |  | $ 233 |  |  |  |  |  |  |  |  |  |  |  |  |
Other (Income) Expense | Arcus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment |  |  |  |  | $ 87 |  |  |  |  |  |  |  |  |  |  |  |  |
CymaBay |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total consideration transferred |  |  |  | $ 3,900 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  | $ 3,900 |  |  |  |  | $ 3,900 |  |  |
Share-based compensation expense |  |  |  |  |  |  |  |  |  | 133 |  |  |  |  |  |  |  |
Asset acquisition, assets acquired |  |  |  | 263 |  |  |  |  |  | 263 |  |  |  |  |  |  |  |
Asset acquisition, liabilities assumed |  |  |  | $ 228 |  |  |  |  |  | 228 |  |  |  |  |  |  |  |
Change of control payment |  |  |  |  |  |  |  |  | $ 101 |  |  |  |  |  |  |  |  |
Settlement of remaining liability |  | $ 108 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CymaBay | Janssen Pharmaceutica NV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment to extinguish a future royalty obligation |  |  | $ 320 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CymaBay | Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share-based compensation expense |  |  |  |  |  |  |  |  |  | 67 |  |  |  |  |  |  |  |
CymaBay | Selling, general and administrative expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share-based compensation expense |  |  |  |  |  |  |  |  |  | $ 67 |  |  |  |  |  |  |  |
XinThera, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  | $ 50 |  |  |  |  |  |  | $ 170 |  |  |  |  |
Cash consideration |  |  |  |  |  |  | $ 200 |  |  |  |  |  |  |  |  |  |  |
Maximum potential future milestone payments |  |  |  |  |  |  | $ 760 |  |  |  |  |  |  |  |  |  |  |
Tmunity Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 244 |  |  |  |
Cash consideration | $ 300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tmunity Therapeutics | Tmunity And University Of Pennsylvania |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  | $ 47 |  |  |  |  |  |  |  |  | $ 25 |
Maximum potential future milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000 |  |  |  |

X
- Definition Asset Acquisition, Assets Acquired + References No definition available. + Details
Name: | gild_AssetAcquisitionAssetsAcquired
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Asset Acquisition, Liabilities Assumed + References No definition available. + Details
Name: | gild_AssetAcquisitionLiabilitiesAssumed
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Liabilities Assumed, Change Of Control Payment + References No definition available. + Details
Name: | gild_AssetAcquisitionLiabilitiesAssumedChangeOfControlPayment
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Liability Assumed, Remaining Liability Payment + References No definition available. + Details
Name: | gild_AssetAcquisitionLiabilityAssumedRemainingLiabilityPayment
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Equity Method Investment, Additional Interest Acquired, Shares + References No definition available. + Details
Name: | gild_EquityMethodInvestmentAdditionalInterestAcquiredShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Method Investment, Additional Investment + References No definition available. + Details
Name: | gild_EquityMethodInvestmentAdditionalInvestment
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Method Investment, Option Fee + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOptionFee
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Method Investment, Ownership Interest, Shares + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOwnershipInterestShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Designees On Board Of Directors + References No definition available. + Details
Name: | gild_NumberOfDesigneesOnBoardOfDirectors
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payments For Asset Acquisitions + References No definition available. + Details
Name: | gild_PaymentsForAssetAcquisitions
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments To Extinguish Future Royalty Obligation + References No definition available. + Details
Name: | gild_PaymentsToExtinguishFutureRoyaltyObligation
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential Future Milestone Payments, Maximum + References No definition available. + Details
Name: | gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Performance Obligation, Percentage Of U.S. Profits + References No definition available. + Details
Name: | gild_RevenuePerformanceObligationPercentageOfU.S.Profits
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gild_ArcellxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_CymaBayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_XinTheraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_TmunityAndUniversityOfPennsylvaniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |